Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG)Bożena Katarzyna Budziszewska, Ewa Lech‐Marańda, Aleksander Salomon‐Perzyński et al.|Cancers|2021Cited by 11
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation ProgramTomasz Sacha, Olga Grzybowska‐Izydorczyk, Janusz Kłoczko et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 7
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG)Agnieszka Pluta, Agnieszka Wierzbowska, Tadeusz Robak et al.|Leukemia & lymphoma/Leukemia and lymphoma|2019Cited by 3
Prognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive ChemotherapyMarta Libura, W Wiktor-Jędrzejczak, Karolina Karabin et al.|Cancers|2023Cited by 3
Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study By the Polish Adult Leukemia Group (PALG)Agnieszka Pluta, Agnieszka Wierzbowska, Kamil Brzozowski et al.|Blood|2016Cited by 1